OQS
IMRX icon

Occudo Quantitative Strategies’s Immuneering IMRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,498
Closed -$57K – 1300
2022
Q2 		$57K Buy
+10,498
New +$56K ﹤0.01% 1059

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Occudo Quantitative Strategies's IMRX Position: Q3 2022 in Review

Occudo Quantitative Strategies sold out of Immuneering (IMRX) in Q3 2022, closing a stake of 10,498 shares — an estimated $57K sold.

Occudo Quantitative Strategies first reported a position in IMRX in Q2 2022 and held it in 1 quarter. The position peaked at $57K in Q2 2022. 32 funds tracked by Wall St. Rank hold IMRX as of Q3 2022.

  • Occudo Quantitative Strategies reported no remaining Immuneering position as of Q3 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 10,498 Immuneering shares in Q3 2022, an estimated $57K.
  • Occudo Quantitative Strategies first reported a position in Immuneering in Q2 2022 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Immuneering position peaked at $57K in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Immuneering as of Q3 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.